blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3544593

EP3544593 - PALIPERIDONE FOR TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISM SPECTRUM DISORDER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  29.10.2021
Database last updated on 18.11.2024
FormerRequest for examination was made
Status updated on  30.08.2019
FormerThe international publication has been made
Status updated on  16.06.2018
Most recent event   Tooltip29.10.2021Application deemed to be withdrawnpublished on 01.12.2021  [2021/48]
Applicant(s)For all designated states
Children's Hospital Medical Center
3333 Burnet Avenue
Cincinnati, Ohio 45229 / US
[2019/40]
Inventor(s)01 / ERICKSON, Craig, Andrew
115 Linden Drive
Wyoming OH 45215 / US
02 / PEDAPATI, Ernest, Vijay
8248 Jakaro Drive
Cincinnati OH 45255 / US
03 / WINK, Logan
3951 Mt. Carmel Road
Cincinnati OH 45244 / US
 [2019/40]
Representative(s)Samson & Partner Patentanwälte mbB
Widenmayerstraße 6
80538 München / DE
[2019/40]
Application number, filing date17873707.821.11.2017
[2019/40]
WO2017US62696
Priority number, dateUS201662425665P23.11.2016         Original published format: US 201662425665 P
[2019/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018098115
Date:31.05.2018
Language:EN
[2018/22]
Type: A1 Application with search report 
No.:EP3544593
Date:02.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 31.05.2018 takes the place of the publication of the European patent application.
[2019/40]
Search report(s)International search report - published on:US31.05.2018
(Supplementary) European search report - dispatched on:EP23.10.2020
ClassificationIPC:A61K9/20, A61K9/50, A61K31/519, A61K9/16, A61P25/18, A61K9/00
[2020/28]
CPC:
A61K31/519 (EP,US); A61K9/16 (EP,US); A61K9/4808 (US);
A61K9/50 (EP,US); A61P25/18 (EP,US); A61K9/0095 (EP)
Former IPC [2019/40]A61K9/20, A61K9/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/40]
TitleGerman:PALIPERIDON ZUR BEHANDLUNG VON ARNEIMITTELWIDERSTANDSFÄHIGER REIZBARKEIT UND AUTISMUS-SPEKTRUM-STÖRUNG[2019/40]
English:PALIPERIDONE FOR TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISM SPECTRUM DISORDER[2019/40]
French:PALIPÉRIDONE POUR LE TRAITEMENT D'UNE IRRITABILITÉ RÉFRACTAIRE MÉDICAMENTEUSE ET D'UN TROUBLE DU SPECTRE AUTISTIQUE[2019/40]
Entry into regional phase11.06.2019National basic fee paid 
11.06.2019Search fee paid 
11.06.2019Designation fee(s) paid 
11.06.2019Examination fee paid 
Examination procedure11.06.2019Amendment by applicant (claims and/or description)
11.06.2019Examination requested  [2019/40]
21.05.2021Application deemed to be withdrawn, date of legal effect  [2021/48]
15.06.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/48]
Fees paidRenewal fee
27.11.2019Renewal fee patent year 03
27.11.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2010026254  (KRKA D D NOVO MESTO [SI], et al) [X] 9,11,12,14 * the whole document * * page 1, line 1 - line 8 * * page 4, line 10 - line 27 * * page 20, line 1 - line 4 * * page 22, line 9 - line 13 * * examples 1-15 * * claim - * [Y] 1-4,6-8,13,15;
 [XY]WO2009109993  (TORRENT PHARMACEUTICALS LTD [IN], et al) [X] 9,11,12,14 * page 1, line 3 - line 5 * * page 3, line 22 - page 6, line 27 * * page 15, line 1 - line 15 * * example - * * claim - * [Y] 1-4,6-8,13,15;
 [IY]WO0010572  (SEPRACOR INC [US], et al) [I] 5 * page 1, line 3 - line 5 * * page 2, line 9 - line 11 * * page 4, line 23 - page 5, line 15 * * page 7, line 8 - line 11 * * claim - * [Y] 6-8,13,15
 [XY]  - KIMBERLY A STIGLER ET AL, "Paliperidone for irritability in adolescents and young adults with autistic disorder", PSYCHOPHARMACOLOGY, SPRINGER, BERLIN, DE, (20120503), vol. 223, no. 2, doi:10.1007/S00213-012-2711-3, ISSN 1432-2072, pages 237 - 245, XP035103052 [X] 10 * the whole document * * page 239, line 15 - line 30 * [Y] 1-4,8,13,15

DOI:   http://dx.doi.org/10.1007/s00213-012-2711-3
 [A]  - DE LEON JOSE ET AL, "The pharmacokinetics of paliperidone versus risperidone", PSYCHOSOMATICS, ELSEVIER, ENGLAND, (20091231), vol. 51, no. 1, doi:10.1016/S0033-3182(10)70664-2, ISSN 1545-7206, pages 80 - 88, XP009520624 [A] 1-15 * the whole document * * page 80, column l, line 1 - page 81, column l, line 32 * * page 84, column l, paragraph 2 - page 85, column l, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/S0033-3182(10)70664-2
 [A]  - YOUNGSTER ILAN ET AL, "CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study", DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, HEINEMANN WILLIAM MEDICAL BOOKS, LONDON, GB, (20140930), vol. 56, no. 10, doi:10.1111/DMCN.12470, ISSN 0012-1622, pages 990 - 994, XP009520628 [A] 1-15 * the whole document * * abstract *

DOI:   http://dx.doi.org/10.1111/dmcn.12470
International search[XY]WO2010026254  (KRKA D D NOVO MESTO [SI], et al) [X] 1-2, 3/1-2, 15-17 * ; page 1, paragraph [2]; page ' 7, paragraph [3]; page 8, paragraph [2]; page 14, paragraph [1]; page 20,.paragraph [1]; page 22, paragraphs [4]-[5]; page 23, paragraph [1] claims 1, 13 ' * [Y] 18/16-17;
 [X]US2015147398  (GUTIERRO ADURIZ IBON [ES], et al) [X] 14 * paragraphs [0013]-[0015], [0051] *;
 [Y]US2010159033  (GANT THOMAS G [US], et al) [Y] 18/16-17 * ; paragraphs [0002], [0012]-[0013], [0035], [0089], [0095] *;
 [A]US2015196501  (ERICKSON CRAIG ANDREW [US], et al) [A] 6-7, 8/6-7, 13, 20 * ; abstract; f paragraphs [0003], [0031] *;
 [A]US2009163519  (VERMEULEN AN [BE], et al) [A] 6-7, 8/6-7, 13, 20 * ; paragraphs [0002], [0007] f *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.